China Animal Vaccine Industry Report, 2011-2012
Research In China, June 2012, Pages: 117
Along with the frequent outbreaks of animal epidemics, the government's increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine market shows vigorous development. In 2011, the market size of animal vaccine in China hit RMB7.92 billion. Since 2004, foot-and-mouth disease, highly pathogenic avian influenza (HPAI), highly pathogenic porcine reproductive and respiratory syndrome (HP-PRRS), swine fever and peste des petits ruminants have been brought into the scope of compulsory immunization by the government, which promotes the animal vaccine market to grow 28.1% annually. It is expected that Chinese market size of animal vaccine will amount to RMB9.56 billion in 2012.
Pig and poultry raising is the backbone of Chinese animal husbandry, and the swine and poultry vaccines occupy more than 80% of China's animal vaccine market. In 2011, the total sales of animal vaccines produced by Chinese animal vaccine enterprises approximated RMB7.11 billion (excluding net import value), of which the sales of swine vaccine and poultry vaccine registered RMB3.51 billion and RMB3.01 billion respectively, making up 49.4% and 42.3% of the total sales separately.
Chinese animal vaccine industry features high degree of industry concentration. In 2011, among major Chinese animal vaccine manufacturers, China Animal Husbandry Industry Co., Ltd. ranked No. 1 for its revenue of RMB1.18 billion, accounting for 14.9% market share. Moreover, the companies with market share of over 5.0% also include Xinjiang Tecon Animal Husbandry Bio-technology Co., Ltd., Guangdong Dahuanong Animal Health Products Co., Ltd. and Jinyu Group. As the state strengthens the regulatory oversight and the consumer's brand awareness is improving, the concentration degree of Chinese animal vaccine industry will be enhanced as well.
Key Topics Covered:
- The market size, market structure, competitive landscape and technology development direction of the global animal vaccine industry;
- The market size, import & export, profit, entry barriers, competition pattern and entry of foreign capital of Chinese animal vaccine industry;
- Policy environment, compulsory immunization tendering system, reform direction and its influence on downstream husbandry development;
- The forecasts of Chinese animal vaccine industry, including overall market, swine vaccine, poultry vaccine, cattle & sheep vaccine and pet vaccine, etc.;
- Production, operation, investment, M&A, clients and suppliers, animal vaccine business and development forecast of 11 major animal vaccine enterprises in China.
1. Overview of Animal Vaccine
1.1 Definition
1.2 Classification
1.3 Industry Chain
2. Status Quo of Animal Vaccine Industry
2.1 Global Market
2.1.1 Market Size
2.1.2 Market Structure
2.1.3 Competitive Landscape
2.1.4 New Epidemics and Products
2.2 Chinese Market
2.2.1 Market Size
2.2.2 Import and Export
2.2.3 Profit
2.2.4 Entry Barriers
2.2.5 Competitive Landscape
3. Development Environment of Animal Vaccine Industry in China
3.1 Policy Environment
3.1.1 Major Policies
3.1.2 Tendering System for Compulsory Immunization Vaccine
3.2 Social Environment
3.2.1 Rapid Development of Husbandry
3.2.2 Large-scale Husbandry Becomes a Trend
3.2.3 Frequent Outbreaks of Animal Epidemics
4. Development Forecast of Animal Vaccine Industry in China
4.1 Overall Forecast
4.2 Swine Vaccines
4.3 Poultry Vaccines
4.4 Cattle & Sheep Vaccines
4.5 Pet Vaccines
5. Key Enterprises
5.1 CAHIC
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 Clients and Suppliers
5.1.6 Animal Vaccine Business
5.1.7 Forecast and Outlook
5.2 Jinyu Group
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D and Investment
5.2.6 Clients
5.2.7 Animal Vaccine Business
5.2.8 Forecast and Outlook
5.3 Tecon
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R& D and Investment
5.3.6 Clients and Suppliers
5.3.7 Animal Vaccine Business
5.3.8 Forecast and Outlook
5.4 Tech-bank
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R&D and Investment
5.4.6 Clients and Suppliers
5.4.7 Animal Vaccine Business
5.4.8 Forecast and Outlook
5.5 Shenghua Biok
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 Clients and Suppliers
5.5.6 Animal Vaccine Business
5.5.7 Forecast and Outlook
5.6 Huasun Group
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Clients and Suppliers
5.6.6 Animal Vaccine Business
5.6.7 Forecast and Outlook
5.7 Harbin Pharmaceutical Group
5.7.1 Profile
5.7.2 Animal Vaccine Business
5.8 Ringpu Bio-technology
5.8.1 Profile
5.8.2 Operation
5.8.3 Revenue Structure
5.8.4 Gross Margin
5.8.5 R&D and Investment
5.8.6 Clients and Suppliers
5.8.7 Animal Vaccine Business
5.8.8 Forecast and Outlook
5.9 Dahuanong
5.9.1 Profile
5.9.2 Operation
5.9.3 Revenue Structure
5.9.4 Gross Margin
5.9.5 R&D and Investment
5.9.6 Clients and Suppliers
5.9.7 Animal Vaccine Business
5.9.8 Forecast and Outlook
5.10 Yikang
5.10.1 Profile
5.10.2 Operation
5.10.3 Revenue Structure
5.10.4 Gross Margin
5.10.5 R&D and Investment
5.10.6 Clients and Suppliers
5.10.7 Animal Vaccine Business
5.11 Chopper
5.11.1 Profile
5.11.2 Operation
5.11.3 Revenue Structure
5.11.4 Gross Margin
5.11.5 R&D and Investment
5.11.6 Clients and Suppliers
5.11.7 Animal Vaccine Business
- CAHIC
- Chopper
- Dahuanong
- Harbin Pharmaceutical Group
- Huasun Group
- Jinyu Group
- Ringpu Bio-technology
- Shenghua Biok
- Tech-bank
- Tecon
- Yikang
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
This title is also available in the following language
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
